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Background: Amyotrophic lateral sclerosis (ALS) is a relatively rare neurodegenerative 
disorder of both upper and lower motoneurons. Currently, the management of ALS is essentially 
symptoms-based, and riluzole, an antiglutamatergic agent, is the only drug for the treatment of 
ALS approved by the food and drug administration.
Objective: We reviewed current literature concerning emerging treatments for amyotrophic 
lateral sclerosis.
Methods: A Medline literature search was performed to identify all studies on ALS treatment 
published from January 1st, 1986 through August 31st, 2009. We selected papers concerning 
only disease-modifying therapy.
Results: Forty-eight compounds were identified and reviewed in this study.
Conclusions: Riluzole is the only compound that demonstrated a beneficial effect on ALS 
patients, but with only modest increase in survival. Although several drugs showed effective 
results in the animal models for ALS, none of them significantly prolonged survival or improved 
quality of life of ALS patients. Several factors have been implicated in explaining the predomi-
nantly negative results of numerous randomized clinical trials in ALS, including methodological 
problems in the use of animal-drug screening, the lack of assessment of pharmacokinetic profile 
of the drugs, and methodological pitfalls of clinical trials in ALS patients.
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Introduction
Amyotrophic lateral sclerosis (ALS) is a relatively rare neurodegenerative disorder 
characterized by progressive loss of both upper and lower motor neurons in the brain, 
brainstem, and spinal cord. The progression of the disease is usually rapid, leading to 
death on average within 3–5 years.1
The underlying cause of ALS remains unclear, but an interplay between endogenous 
(genetic, metabolic) and exogenous factors (environmental, lifestyle) is believed to be 
involved in the development of the disease.2,3
Although ALS usually develops sporadically, 5%–10% of cases are familial and 
hereditary. Twenty percent of familial ALS are caused by the mutation in Cu/Zn 
superoxide dismutase-1 (SOD1) gene.1
The development of animal models of ALS has provided progress in understanding 
the underlying mechanisms of the disease because the sporadic and the familiar forms 
of ALS share similar clinical and pathological features.3,4
Several animal models have been extensively used in ALS through the years, 
including different transgenic mouse models, wobbler mouse and one canine model.3,4 Neuropsychiatric Disease and Treatment 2009:5 578
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The most clinically relevant animal model of ALS is the 
SOD1 transgenic rodent (mainly mice) model, that is geneti-
cally engineered to express a mutant form of the human 
SOD1 gene. The most commonly used SOD1 mouse har-
bors the glycine to alanine mutation at position 93 (G93A). 
This mutation results in a toxic gain of function of Cu/Zn 
SOD1 that enhances the generation of damaging oxygen 
radicals.3
A wide range of mechanisms are thought to be impli-
cated in the pathogenesis of the disease: these include 
mitochondrial dysfunction, excitotoxicity, oxidative stress, 
protein misfolding, proteosomal dysfunction, aberrant 
growth factor signaling, microinflammatory process and 
glial activation.2–5
Riluzole, an antiglutamatergic agent that inhibits the 
presynaptic release of glutamate, is the only drug for the treat-
ment of ALS approved by the US Food and Drug Administra-
tion (FDA).6 However, it is known to have limited therapeutic 
benefits and only modest effects on survival of ALS patients.6 
Therefore, to date there is no effective cure for ALS and the 
management of ALS in clinical practice remains essentially 
supportive and symptoms-based.6,7
In recent years, great efforts have been made in the 
search for effective treatments of ALS; a large number of 
neuroprotective agents have been proposed candidates for 
the treatment of ALS and several clinical trials have been 
planned and conducted.8 The purpose of this review is to 
summarize the current and emerging treatments for amyo-
trophic lateral sclerosis.
Methods
A Medline literature search was performed to identify all 
studies on neuroprotective treatment of ALS published 
from January 1st, 1986 through August 31st, 2009, using 
the MeSH terms “motor neuron disease”, “motor neurons”, 
“amyotrophic lateral sclerosis”, “treatment”, “therapy”, 
“clinical trials”, “experimental studies”, and “drugs”. Articles 
and abstracts were included only when published in English. 
Additional references were taken from article citations. 
For the purpose of this review we considered only disease-
modifying therapy.
Results
Following data extraction, we identified a group of 48 poten-
tial therapeutic agents. These compounds were grouped and 
reviewed based on their hypothetical mechanisms of action 
(Table 1). A list of undergoing clinical trials for ALS is also 
reported (Table 2).
Antiglutamate agents
riluzole
Riluzole is an antiglutamatergic agent thought to inhibit the 
presynaptic release of glutamate.9 In a mouse model of ALS, 
treatment with riluzole significantly delayed the onset of the 
disease and slowed the decline in motor function.8,9 Recently, 
a systematic review of ALS treatment with riluzole has been 
performed by the Cochrane Neuromuscular Diseases group.6 
The review included four clinical trials (overall number of 
treated patients: 1,477).6 Based on this meta-analysis, riluzole 
treatment with 100 mg daily was considered safe, well 
tolerated and was associated with a statistically significant 
improvement in tracheostomy-free survival. The effect size 
was however small, as the median increase in survival is 
about two to three months.6
Results from population-based studies indicated that 
riluzole therapy increased survival rates at 12 months by 
approximately 10% and prolonged survival by 4–6 months.10,11 
One study observed also a stronger beneficial effect amongst 
bulbar-onset ALS and patients aged 70 years (increase in 
median survival time: eight months).11 The favorable effect 
of the drug was transient and lost in prolonged follow-up 
(after 18 months).10,11 A study on transgenic rats demonstrated 
that the deficit in glutamate uptake becomes more severe by 
end-stage of the disease and is probably the cause for the loss 
of efficacy of the drug in advanced ALS.12 More studies are 
therefore needed, especially to clarify the effects of riluzole 
in older patients, in bulbar-ALS, and in patients with more 
advanced disease.
Memantine
Memantine is a low-affinity, noncompetitive antagonist 
of both open-channel N-methyl-D-aspartate (NMDA) 
and α-calcium-permeable-amino-3-hydroxy-5-methyl-
4-isoxazole propionic acid (AMPA) glutamate receptors.13,14 
It permits the blockade of excessive NMDA receptors 
activity, without disrupting normal synaptic transmission.13 
Various in vitro and in vivo models of excitotoxicity showed 
that memantine has neuroprotective properties14 and the 
drug has been used clinically with excellent safety in 
various neurodegenerative disorders, including Alzheimer’s 
disease.15 Two recent animal studies on SOD1 transgenic 
mice found that the drug is effective in slowing progression 
and increasing survival of transgenic mice.16,17 In one study, 
the administration of memantine had therapeutic effects, 
even when given at symptoms onset.17 Data on ALS patients 
are lacking, although one phase II clinical trial in US and 
combined phase II–III clinical trials are ongoing.18Neuropsychiatric Disease and Treatment 2009:5 579
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Table 1 List of drugs tested in ALS, with hypothetical mechanisms of action and currently available results
Compound Mechanism  
of action
Principal results
riluzole Antiglutamatergic Preclinical studies with positive results8,9
in three clinical trials was associated with increase in survival of about two 
months6
results from population-based studies indicated an increase in survival rates at 
12 months by 10% and in median survival by 4–6 months10,11
A trend for stronger benefice amongst bulbar-onset ALS and patients 
aged 70 years was also observed10,11
The favorable effect was transient, as it was lost in prolonged follow-up 
(after 18 months)10,11
Memantine Antiglutamatergic Neuroprotective in in vitro and in vivo studies14
Positive preclinical studies on SOD1 transgenic mice16,17
No data on humans
L-Arginine Antiglutamatergic Positive preclinical studies on SOD1 transgenic mice19
Lower plasma L-arginine levels in ALS patients20
No clinical trials on ALS patients
Ceftriaxone Antiglutamatergic Positive preclinical studies on SOD1 transgenic mice21,22
Limited data on humans
Cobalamin Antiglutamatergic Two trials on SOD1 transgenic mice gave positive results26,27
A small double-blind trial found that short term (four weeks) high-dosage 
(0.5 mg/day) was effective in improving compound motor action potential, used 
as indicator of lower motoneuron number28
Patients with a good response to treatment presented slower disease 
progression (disease duration: 23.1 vs 18.8 months; P = 0.02)28
The clinical benefit was however transient, as it was followed by deterioration 
after 1–3 months28
Talampanel Antiglutamatergic Prolongs survival in SOD1 transgenic mice8
in a phase ii study on 60 patients with ALS showed safe and well tolerated 
results8,23
No data on efficacy
N-acetylated alpha-linked 
acidic dipeptidase
Antiglutamatergic Positive results from in vivo studies on motor neurons31 and in vivo studies on 
SOD1 transgenic mice30
No data on safety and efficacy in ALS patients
Topiramate Antiglutamatergic Preclinical studies with conflicting results: effective in vitro, but not in vivo32
A randomized clinical trial showed no benefits. Patients receiving the drug had 
more pulmonary emboli, deep vein thrombosis, and renal calculi33
Gabapentin Antiglutamatergic Preclinical results with gabapentin suggested that this agent may prolong motor 
neuron survival34
A phase ii randomized trial found a slowing of the rate of strength decline35
A phase III clinical trial found no benefit on survival36
Lamotrigine Antiglutamatergic Animal model with axotomy gave positive results38
Two small sample randomized clinical trials found no beneficial effects on 
survival and markers of motor performances39,40
r-iGF-1 Neuroprotective In vitro and in vivo studies gave positive results41
A first clinical trial found beneficial effect,42 while two further clinical trials gave 
negative results43,44
Mechano-growth factor Neuroprotective A variant of iGF-1 was more effective on survival of SOD1 transgenic mice, 
compared to iGF-147
No data on humans
Ciliary neurotrophic factor Neuroprotective Preclinical study with positive results48
Two clinical trials revealed it was ineffective in ALS patients50,51
A trend for higher serious adverse events was noted50,51
ePO Neuroprotective 
Anti-inflammatory 
Antiapoptotic
Neuroprotective effects in in vivo and in vitro studies53,54
Safe and well tolerated in a phase ii clinical trial55
No data on efficacy in humans
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Table 1 (Continued)
Compound Mechanism  
of action
Principal results
veGF Neuroprotective (against 
excitotoxicity)
veGF polymorphisms have been associated with an increased risk for ALS23
Preclinical studies found efficacy on SOD1 transgenic mice56,57
No data regarding safety, tolerability or efficacy in humans.
The compound requires intrathecal delivery23
A phase ii clinical trial is underway24
rh-GSF Neuroprotective
Antiapoptotic
Preclinical studies on ALS animal models gave positive results60
Safe and well tolerated in two small sample open-label pilot studies6,62
One study found a trend of slowing disease progression62
rh-HGF Neuroprotective
Antiapoptotic
Antiglutamatergic
Prolonged survival in different studies on SOD1 animal models63–65
Safety or efficacy data in patients with ALS are lacking and the compound 
requires intrathecal delivery
BDNF Neuroprotective Positive results in preclinical studies on ALS animal models68,69
A trend for prolonged survival after the subcutaneous infusion of BDNF was 
found in a phase i/ii study70
A large phase III placebo-controlled clinical trial found no beneficial effect from 
subcutaneous administration of BDNF71
intrathecal infusion was safe and well tolerated in 25 ALS patients66
GDNF Neuroprotective Treatment with GDNF mediated by either 
an adeno-associated virus vector72–74 or 
by mesenchimal stem cells75,76 was effective in preclinical in vitro and in vivo studies
No data on ALS patients
Xaliproden Neuroprotective Modest effects on vital capacity but not on survival in phase ii and iii clinical 
trials79,80
Coenzyme Q Antioxidant
Mitochondrial cofactor
Prolongs survival in SOD1 transgenic mice81
Safe and well tolerated in a recent phase ii clinical trial82
Not effective in a phase ii futility trial83
Creatine Antioxidant
Mitochondrial cofactor
Preclinical studies with positive results23,84
Several phase ii clinical trials on ALS patients using doses up to 10 g/day gave 
negative results85–87
Treatment with 20 g/day increases maximal isometric power in ALS patients88
Clinical trials using high dosage or a combination with celecoxib are ongoing24
vitamin e Antioxidant effective in ALS animal models9
High intake of vitamin e was associated with a 50%–60% decreased risk of devel-
oping ALS, in a recent retrospective case-control study93
Safe, well tolerated, but not effective in two double blind, placebo-controlled, 
clinical trials as add-on to riluzole91,92
edavarore Antioxidant
(Free-radicals scavenger)
Preclinical studies with positive results94
was safe and well tolerated and there was a suggestion of slowed disease pro-
gression in an open-label phase ii study95
r(+) Pramipexole Antioxidant
Antiapoptotic
Prolonged survival in an animal study on SOD1 transgenic mice96
A nonsignificant reduction in disease progression was observed in a recent phase II 
clinical study97
AeOL-10150 Antioxidant effective in prolonging survival in animal study on SOD1 transgenic mice99–101
in a recent open-label study on patients with ALS was safe and well tolerate102
Ammonium 
tetrathiomolybdate
Antioxidant
(copper-chelating drug)
Positive preclinical studies on SOD1 transgenic mice104
No data on humans
N-acetylcysteine Antioxidant Prolonged survival and delayed onset of motor impairment in ALS animal study105
Not effective in a double-blind placebo-controlled clinical trial106
TrO19622 Antioxidant Positive results from in vitro and in vivo studies107
No data on ALS patients
Tamoxifen Antioxidant A phase II clinical trial indicated a trend for survival benefit with administration 
of tamoxifen at the dose of 20 mg/day108
(Continued)Neuropsychiatric Disease and Treatment 2009:5 581
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Table 1 (Continued)
Compound Mechanism  
of action
Principal results
Minocycline Antiapoptotic
Anti-inflammatory
extends survival in mouse models of some neurological conditions109–111
Safe and well tolerated in phase-ii clinical trials112
A recent multicenter, randomized placebo-controlled phase iii trial found that 
minocycline in escalating doses of up to 400 mg/day for nine months has a harmful 
effect on patients with ALS113
TCH-346 Antiapoptotic A small sample double-blind placebo controlled clinical trial conducted find no 
beneficial effects114
zvAD-fmk Antiapoptotic Significantly delayed disease onset and prolonged survival in SOD1transgenic 
mice116
Data on ALS patients are still not available
Pentoxifylline Antiapoptotic A large phase ii randomized clinical trial found that the drug is not effective in 
ALS and should be avoided in patients treated with riluzole117
Celecoxib Anti-inflammatory (cyclo-
oxygenase-2 inhibitor)
Positive preclinical studies on SOD1 transgenic mice119,120
A double-blind, placebo-controlled, clinical trial demonstrated that celecoxib 
(800 mg/day) was safe but did not have a beneficial effect on patients with ALS121
A clinical trial evaluating the association with creatine at high dose is underway24
Glatiramer acetate Anti-inflammatory
Antiglutamatergic growth 
factor-stimulating effects
Conflicting results from preclinical studies: some studies found that it prolonged 
survival in SOD1 mutant mice,124 while others did not125
was safe and well tolerated in a phase ii trial126
A double-blind, randomized, placebo-controlled, multicenter trial confirmed 
safety and tolerability but did not show any beneficial effect127
AM-1241 Anti-inflammatory (via 
cannabinoid receptors)
Delayed the disease progression in animal studies128,129
No data on humans are available
Celastrol Anti-inflammatory
Antioxidant
interfere with protein 
aggregation (by heat-shock 
protein induction)
Significantly improved weight loss, motor performance and
delayed the onset of ALS in SOD1 transgenic mice130
No data on humans are available
Thalidomide Anti-inflammatory enhanced motor performance, decreased motor neuron cell death, and 
significantly increased the life span in animal studies131
A small open-label study find no improvement in progression of the disease and 
a high risk for side effects132
Nordihydroguaiaretic acid Anti-inflammatory
Antiglutamatergic
extends survival and slows disease progression in animal studies135
No data are available on humans
Pioglitazone Anti-inflammatory Significantly improved muscle strength and body weight, delayed disease onset, 
and prolonged survival in SOD1 transgenic mice136–138
No data are available on humans
rO-28-2653 Anti-inflammatory (inhibits 
matrix metalloproteases)
Prolongs survival in ALS SOD1 transgenic mice139
No data on humans are available
ONO-2506 Anti-inflammatory 
restores astrocytes 
Antiglutammatergic
Limited data on preclinical studies and on humans140
Trials have been however recently completed
Lithium inductor of autophagy
Antioxidant
effective in preclinical studies on SOD1 transgenic mice141
in a small sample open label study delayed disease progression in 44 patients 
affected by ALS141
Two large clinical trials are ongoing24
Sodium phenylbutyrate inhibit protein aggregation
(histone deacetylase 
inhibitor)
Promotes cell survival, alone or in combination with riluzole in animal 
studies144,145
Safe and well tolerated in a recent open-label study146
valproate inhibit protein aggregation
(histone deacetylase 
inhibitor)
Preclinical studies on SOD1 mutant mice gave discordant results; 149–152 some 
studies found that it prolongs survival,149,150 while others did not151,152
Safe but not effective in a recent sequential clinical trial 153
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Table 1 (Continued)
Compound Mechanism  
of action
Principal results
Scriptaid inhibit protein aggregation
(histone deacetylase 
inhibitor)
Preliminary positive results in cultural cells transfected with SOD1154
No data on animal models and humans are available
Ariclomol inhibit protein aggregation
(by heat-shock protein 
induction)
effective in preclinical studies155,156
Safe and well tolerated in a phase ii clinical trial157
No data on efficacy on ALS patients
Abbreviations: ALS, amyotrophic lateral sclerosis; r-iGF-1, recombinant insulin-like growth factor; ePO, recombinant human erythropoietin;   veGF, vascular endothelial growth 
factor; rh-GSF, recombinant human granulocyte-macrophage colony-stimulating factor; rh-HGF, recombinant human hepatocyte growth factor; BDNF, brain-derived neurotropic 
factor; GDNF, glial cell-derived neurotropic factor; SOD1, superoxide dismutase-1.
L-Arginine
L-Arginine is a semiessential amino acid that serves as sole 
substrate for enzymes involved in diverse cell processes. 
Preclinical studies have found that L-arginine protects cul-
tured motor neurons from glutamate excitotoxic injury.19 
The mechanism underlying these favorable effects is still 
not known but may be related to the synthesis of neuro-
protective polyamines, essential for neuronal survival 
and regeneration.19 L-Arginine supplementation in SOD1 
transgenic ALS mice, administrated both prior to and 
after the onset of motor neuron degeneration, significantly 
slowed the progression of neuropathology in lumbar spinal 
cord, delayed onset of motor dysfunction, and prolonged 
life span.19 Moreover, lower plasma L-arginine concentra-
tions have been reported in ALS patients, probably due to 
malnutrition associated with advanced ALS.20 Although 
L-arginine has potent in vitro and in vivo neuroprotective 
properties and may be a candidate for therapeutic trials in 
ALS, data on humans are lacking.8,18
Ceftriaxone
Ceftriaxone, a beta-lactam antibiotic, modulates the expression 
of glutamate transporter GLT1 via gene activation and may also 
act as metal chelator.21 Preclinical studies demonstrated that it 
prolongs survival in different animal models of ALS.21,22 This 
compound has been used extensively in humans and is safe.23 
However, intravenous administration is required and there is 
limited safety experience in ALS patients.23 A combined long-
term clinical trial of intravenous treatment with ceftriaxone has 
been started. The study consists of three stages. The first two 
stages will evaluated brain penetration, safety and side effects. 
The third stage will determine whether the study drug prolongs 
survival and slows decline in function due to ALS.18,24
Cobalamin
Vitamin B12 (cobalamin) has multiple protective effects 
that can be potentially relevant in ALS. Accumulating 
evidence indicates that B-vitamin inhibits the cytotoxicity 
induced by NMDA and protects cultured neurons against 
glutamate excitotoxicity.25 Cobalamin also has antioxidant 
and antiapoptotic properties.26 In two controlled trials 
on G93A SOD1 transgenic mice, multivitamin therapy 
with cobalamin, folic acid and pyridoxine significantly 
prolonged average lifespan improved motor performance 
and delayed disease onset of treated mice, compared to 
controls.26,27 Furthermore, cobalamin administrated pre-
symptomatically significantly delayed the onset of motor 
neuron disease in one of the studies.26 In a small sample 
double blind clinical trial conducted on 24 Japanese ALS 
Table 2 List of compounds undergoing clinical trials for ALS163
Compound Phase Mechanism of action
Ariclomol ii/iii Heat-shock protein induction
Ceftriaxone ii/iii Antiglutamatergic
Cobalamin ii/iii Antiglutamatergic
Creatine ii/iii Antioxidant
Celecoxib Anti-inflammatory
edavarore ii/iii Free-radicals scavenger
reduces mutant SOD1 deposition
Lithium a) ii/iii inductor of autophagy
b) ii/iii
Memantine ii/iii Antiglutamatergic
Pioglitazone ii Anti-inflammatory
r(+) pramipexole ii Antioxidant
Antiapoptotic
Talampanel ii Antiglutamatergic
Thalidomide a) i Anti-inflammatory
b) ii
valproate ii/iii inhibits protein aggregation by acting as 
a histone deacetylase inhibitor
veGF ii Protects motor neurons against 
excitotoxicity
Abbreviations: ALS, amyotrophic lateral sclerosis; SOD1, superoxide dismutase-1; 
veGF, vascular endothelial growth factor.Neuropsychiatric Disease and Treatment 2009:5 583
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patients short term (four weeks) high-dosage (0.5 mg/day) 
administration of methyl-cobalamin was effective in improv-
ing compound motor action potential, used as indicator of 
lower motoneuron number.28 Patients with a good response 
to treatment presented slower disease progression (disease 
duration: 23.1 vs 18.8 months; P = 0.02) and predominant 
lower motor neuron involvement, compared to nonre-
sponders.28 The clinical benefit however was transient, 
as it was followed by deterioration after 1–3 months.28 
A large-scale long-term clinical trial is ongoing in Japan 
to evaluate the long-term efficacy and the safety of ultra-
high-dose methylcobalamin for ALS.29
Talampanel
Talampanel is a noncompetitive modulator of glutamate 
AMPA glutamate receptors primarily developed as an 
antiepileptic agent. Talampanel significantly prolonged 
survival in SOD1 ALS transgenic mice.8 In a phase II study 
on 60 patients with ALS, talampanel was safe and well 
tolerated.8,23 A trend for slower decline in ALS Functional 
Rating Scale (ALS-FRS) score was also observed in the 
treated subgroup, although the study was not powered to 
detect efficacy.8,23 Therefore, there are still no data on its 
efficacy on patients with ALS.
N-acetylated alpha-linked acidic dipeptidase 
(NAALADase)
N-acetylated alpha-linked acidic dipeptidase (NAALADase) 
is an inhibitor of glutamate carboxypeptidase II, which 
converts the neuropeptide N-acetylaspartylglutamate to 
glutamate.30 Glutamate carboxypeptidase II inhibitors may 
provide neuroprotection by simultaneously decreasing 
glutamate production and inhibiting glutamate release.30 Pre-
clinical in vitro studies in SOD1 transgenic mice found that 
treatment with selective inhibitors of glutamate carboxypep-
tidase II significantly delays the onset of clinical symptoms 
and prolongs life.30 Glutamate carboxypeptidase II inhibitors 
were protective against histological abnormalities induced by 
mutant SOD1in in vitro studies on motor neurons cultures.31 
In phase I single dose and repeat dose trials treatment with 
NAALADase was safe and well tolerated by both healthy 
volunteers and diabetic patients.30 There are however still no 
data on safety and efficacy in ALS patients.
Topiramate
Topiramate is an anticonvulsant with antiglutamatergic 
properties. It reduces glutamate release from neurons and 
blocks AMPA receptors. In vitro studies found that topira-
mate protects motor neurons in an organotypic spinal cord 
culture system in which glutamate transport is inhibited by 
pharmacological blockade.32 Conversely, the drug did not 
increase survival in G93A SOD1 transgenic mice.32
A randomized placebo controlled clinical trial has been 
recently conducted in 296 ALS patients from the US. Patients 
were randomized (2:1) to receive topiramate (maximum toler-
ated dose up to 800 mg/day) or placebo for 12 months.33 At the 
dosages studied, topiramate did not have a beneficial effect for 
patients with ALS. Moreover, high-dose topiramate treatment 
was associated with a faster rate of decline in muscle strength 
and with an increased risk for several adverse events, such as 
pulmonary emboli, deep vein thrombosis, and renal calculi.33
Gabapentin
Gabapentin is another antiepileptic drug with antiglutamatergic 
properties. Gabapentin may reduce the pool of releasable glu-
tamate and thus decrease glutamate excitotoxicity.34 Preclinical 
studies with gabapentin suggested that this agent may prolong 
motor neuron survival.35 A six-month phase II randomized 
trial in 150 patients with ALS found a nonstatistically signifi-
cant trend towards slowing of the rate of strength decline in 
patients taking gabapentin (up to 2,400 mg day), compared 
with those taking placebo (mean difference 24%, median 37%; 
P = 0.057).35 In a phase III randomized placebo controlled clini-
cal trial 204 ALS patients received oral gabapentin 3,600 mg 
or placebo daily for nine months. The mean rate of decline of 
the arm muscle strength was not significantly different between 
the groups.36 Moreover, there was no beneficial effect on the 
rate of decline of other secondary measures, as vital capacity, 
survival and ALS-FRS score.36 Confirming these findings, a 
recent small proton magnetic resonance spectroscopy study on 
18 ALS patients showed that treatment with gabapentin was 
not associated with improvement in spectroscopic markers of 
neuronal integrity in motor and nonmotor cerebral regions.37
Lamotrigine
Lamotrigine is an antiepileptic drug that inhibits glutamate 
release.38 Treatment with lamotrigine was associated with 
a reduction in motor neuron loss in an animal model using 
axotomy.38 Two small sample, randomized phase I clinical 
trials found no beneficial effects on survival and markers of 
motor performances on total 97 ALS patients.39,40
Neurotrophic factor
recombinant insulin-like growth factor (riGF-1)
Recombinant insulin-like growth factor (r-IGF-1) is a potent 
neurotrophic factor that has neuroprotective properties in the 
central and peripheral nervous systems.41 Due to the efficacy Neuropsychiatric Disease and Treatment 2009:5 584
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of IGF-I in the treatment of other diseases and its ability to 
promote neuronal survival in both in vitro and in vivo studies, 
IGF-I has been extensively studied in ALS.23,41
The efficacy and safety of r-IGF-1in ALS has been tested 
in three clinical trials.42–44 With the exception of an increased 
risk of injection site reactions with r-IGF-I, the drug showed 
otherwise safe and well tolerated results. However, the benefit 
on survival was inconsistent across the studies. One study 
showed a slowing in functional decline,42 whilst no benefit 
was observed in the second.43 The combined analysis from 
both trials performed by the Cochrane Group showed a trend 
towards for beneficial effect favoring the treated group.45 
A third placebo-controlled trial has been recently completed.44 
There was no difference between treatment groups in the 
primary and secondary outcome measures after a two-year 
follow-up period.44 In conclusion, r-IGF-I is well tolerated but, 
although so far is the only agent other than riluzole to show 
on any ALS markers of disease progression, can not be con-
sidered beneficial for patients with ALS. Recently, an adeno-
associated virus has been engineered to contain the gene for 
IGF-1 (IGF-1/AAV).23 Theoretically, after the intramuscular 
injection, this vector could allow to deliver IGF-1 to motor 
neurons.23 Preclinical studies revealed that IGF-1/AAV can 
prolong survival in SOD1 ALS transgenic mice.46 However, 
there are no data on safety, tolerability or pharmacokinetics 
of IGF-1/AAV in humans with ALS.
Mechano-growth factor (MGF)
The mechano-growth factor (MGF), an IGF-I splice variant, 
has been shown to have greater neuroprotective effects than 
IGF-I in a number of models of neurodegeneration.23 In an 
animal study on SOD1 transgenic mice the intramuscular 
administration of a mammalian expression plasmid contain-
ing MGF or, for comparison, the IGF-I DNA sequence resulted 
in a significant improvement in hind-limb muscle strength, and 
an increase in motor unit and motor neuron survival.47 Signifi-
cantly more motor neurons survived in MGF treated mice.47 
There are still no data on safety and efficacy in humans.
Ciliary neurotrophic factor (CNTF)
Ciliary neurotrophic factor (CNTF) is a neuroactive cytokine 
found in Schwann cells, which seems to be released in response 
to nerve injury.23 CNTF maintains survival of adult motor neu-
rons and mice lacking the CNTF gene develop mild, progres-
sive motor neuron loss.48 In a recent study, serum level of CNTF 
was significantly higher in ALS patients than in controls.49 
There was no difference between familial and sporadic ALS, 
and a trend for higher levels was observed in patients with 
spinal-onset ALS, compared to patients with a bulbar onset 
of the disease.49 ALS patients in two trials (n = 1,300) were 
treated with subcutaneous CNTF.50,51 No significant difference 
in either primary or secondary outcomes was observed between 
CNTF and placebo groups.50–52 However, a significant increase 
of the incidence of several adverse events was noted in groups 
treated with higher doses of CNTF.52 Therefore CNTF can not 
be considered beneficial for patients with ALS.
recombinant human erythropoietin (ePO)
Recombinant human erythropoietin (EPO) is used to 
stimulate red blood cell production in patients with anemia. 
Preclinical studies in different models of peripheral and 
central nervous system diseases revealed that EPO has also 
anti-inflammatory and antiapoptotic properties.53,54 A recent 
phase II double-blind, randomized, placebo-controlled study 
on 23 patients showed that treatment with subcutaneous 
EPO was safe and well tolerated.55 However, larger studies 
are warranted to confirm safety and to investigate different 
dose schedule and efficacy.
vascular endothelial growth factor (veGF)
VEGF polymorphisms have been associated with an 
increased risk for ALS in some, but not all populations.23 
Therefore VEGF deficiency may play a role in the 
pathogenesis of ALS. The most important limitation as for 
other growth factors, is that requires invasive administration 
(intraventricular or via viral vectors).23 Preclinical studies on 
different ALS animal models found that intracerebral or intra-
spinal treatment with VEGF prolongs survival and reduces 
disease progression, particularly when given before the onset 
of symptoms.56,57 In vitro studies showed that VEGF protects 
motor neurons against excitotoxicity.58 Finally, intratechal 
transplantation of neural stem cells overexpressing VEGF 
was effective in several animal studies.59 There are, however, 
no data regarding safety, tolerability or efficacy in humans, 
although a phase II clinical trial is ongoing.24
recombinant human granulocyte-stimulating  
factor (rh-GSF)
Recombinant human granulocyte-stimulating factor 
(rh-GSF), used to stimulate white blood cell production 
in patients with leucopenia, has been proposed for ALS 
because the GSF receptor is expressed by motor neurons, 
has neurotropic effects, and protects cultured motor neu-
ronal cells from apoptosis.60 In a recent animal study, con-
tinuous subcutaneous delivery of GSF, given at the stage 
of the disease where muscle denervation is already evident, 
significantly improved motor performance, delayed the onset 
of severe motor impairment and prolonged overall survival Neuropsychiatric Disease and Treatment 2009:5 585
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of SOD1 transgenic mice model.60 In two small sample 
open-label pilot studies on 39 ALS patients overall, rh-GSF 
was safe and well tolerated.61,62 One study found a trend of 
slowing disease progression following rh-GSF treatment, 
as shown by lower decline of quality of life and ALS-FRS 
score.62 Larger studies are needed.
recombinant human hepatocyte growth  
factor (rh-HGF)
Recombinant human hepatocyte growth factor (rh-HGF) has, 
in addition to its neurotropic effects, antiapoptotic and antiglu-
tammatergic properties.63,64 Intrathecal aministration and gene 
therapy significantly prolonged survival in different studies on 
SOD1 animal models, even if delivered at symptom onset.63–65 
A recent immunohistochemical study on both familial (SOD1) 
and sporadic ALS found that HGF is expressed on the anterior 
horn cells of the spinal cord, supporting the hypothesis that 
disruption of HGF system thereby contributes to the accelera-
tion of neuronal degeneration in FALS patients.66
However, safety or efficacy data in patients with 
ALS are lacking and the compound requires intrathecal 
administration.
Brain-derived neurotrophic factor (BDNF)
Brain-derived neurotrophic factor (BDNF) is a neurotrophin 
that supports the survival and growth of developing motor 
neurons.67 Preclinical studies in several animal models found 
that BDNF treatment significantly prolongs survival and 
slows the loss of motor neurons.8,68,69 In phase I/II study, the 
subcutaneous infusion of BDNF increased survival and retard 
loss of pulmonary function in ALS patients,70 but a large 
phase III placebo-controlled clinical trial of subcutaneous 
administration of 25 or 100 mg/kg n 1.135 ALS patients failed 
to demonstrate a statistically significant effect of BDNF on 
survival.71 Post hoc analyses revealed a statistically significant 
benefit in ALS patients with an early respiratory impairment. 
Higher subcutaneous dosage or an intrathecal delivery have 
been proposed to emphasize the possible beneficial effects 
of the drug. Recently, in a phase I/II trial intrathecal infusion 
of recombinant methionyl human BDNF in doses of up to 
150 mg/day showed safe and well tolerated results in 25 ALS 
patients, although reversible mild sensory symptoms were 
reported in the higher-dosage subgroup.67 Studies on the 
efficacy of intrathecal BDNF are therefore required.
Glial cell-derived neurotrophic factor (GDNF)
Glial cell-derived neurotrophic factor (GDNF) has a 
potent trophic effect on motor neurons.71 Several preclinical 
in vitro and in vivo studies found that treatment with GDNF 
mediated by either an adeno-associated virus vector72–74 or 
by mesenchimal stem cells75,76 is effective in prolonging 
motor neurons survival. Conversely, studies from patients 
with sporadic ALS gave conflicting results.77,78 Increased 
cerebrospinal fluid levels of GDNF in patients with ALS 
compared to controls77 and upregulation of GDNF gene in 
both spinal cord and muscle of sporadic ALS have been 
indeed observed.77,78 These findings indicate that the capacity 
to synthesize GDNF is enhanced in ALS. Clinical trials of 
GDNF in ALS patients are however lacking.
Xaliproden
Xaliproden is a nonpeptidic compound with growth factor 
activities.8 A double-blind, placebo-controlled phase II study 
conducted in 54 ALS patients treated for up to 32 weeks 
showed a significantly slower rate of deterioration in vital 
capacity (VC) (43%; P = 0.046) in xaliproden-treated 
patients.79 Two randomized phase III clinical trials have been 
conducted: one with xaliproden and riluzole and the other with 
xaliproden alone. Two primary endpoints were defined: time 
to death, tracheostomy, or permanent assisted ventilation and 
time to VC of less than 50%.80 The drug demonstrated in both 
studies modest benefits for VC but not for the other endpoints.80 
Therefore the drug is not significantly effective in ALS.
Antioxidant
Coenzyme Q 10
Coenzyme Q 10 has multiple potential mechanisms that can 
be relevant in ALS. It acts as an antioxidant and an essential 
mitochondrial cofactor that facilitates electron transfer in the 
respiratory chain.23 Animal studies revealed that coenzyme 
Q 10 can prolong survival in SOD1 transgenic mice.81 In an 
open-label, dose-escalation study, doses up to 3,000 mg per 
day administered orally over eight months was safe and well 
tolerated in 31 patients with ALS.82 Conversely, results of a 
phase II futility trial on 185 patients showed no benefit on 
survival of 2,700 mg daily oral treatment with coenzyme 
Q 10.83 Long term safety and efficacy in humans are limited, 
but several randomized studies in patients with ALS recently 
terminated recruitment.24
Creatine
Creatine has multiple potential effects that might be relevant in 
ALS, including its antioxidant properties, stabilization of the 
mitochondrial transition pore and facilitation of mitochondrial 
ATP synthesis. Important advantages of creatine are also its 
oral administration, elevate brain penetration and the excellent Neuropsychiatric Disease and Treatment 2009:5 586
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safety profile.8,23 Preclinical studies on SOD1 transgenic mice 
revealed that creatine significantly increases survival, when 
given before the onset of the disease.23,84 Three double blind, 
placebo-controlled clinical trials on creatine monohydrate use 
have been recently conducted.85–87 In one clinical trial creatine 
was administrated at doses of 10 mg/day over a 16-month fol-
low-up period,85 while the other two studies used a dosage of 
5 mg/day over a six- and nine-month period of observation.86,87 
All these studies gave negative results as creatine failed to 
show a benefit on survival or multiple markers of disease 
progression. A possible explanation of these negative results 
may be that these trials did not use doses that optimize brain 
phosphocreatine levels, as preliminary results demonstrated 
that treatment with 20 g/day increases maximal isometric 
power in ALS patients.88 Alternatively, the combination of 
higher doses of creatine with other drugs may be used to 
maximize its benefit, as indicated by results from recent ani-
mal studies.89 Confirming these observations, an innovative 
phase II “selection” trial, in which creatine at 20 g/day was 
used in combination with either minocycline or celecoxib, 
found that the mean decline in ALS Functional Rating Scale 
(ALS-FRS) score was lower in the celecoxib-creatine group 
compared to the minocycline-creatine group and an historical 
cohort.90 The celecoxib-creatine may be therefore a preferable 
combination for further evaluation. Two clinical trials with 
high dose creatine and with celecoxib-creatine association 
are underway.24
vitamin e
Vitamin E (alpha-tocopherol) is the most important lipid-
soluble antioxidant and protects cell membranes from oxi-
dation by reacting with lipid radicals.23 Preclinical studies 
showed that treatment with vitamin E slows down the onset 
and progression of the paralysis in SOD 1 transgenic mice.9 
Two double blind, placebo-controlled, clinical trials on ALS 
patients from Germany and France evaluated the safety 
and efficacy of high-dose vitamin E (5000 mg per day) 
when given added to riluzole, over a follow up period of 18 
and 12 months, respectively.91,92 No significant difference 
between placebo and treatment group could be detected 
either in the primary or the secondary outcome measures, 
although the French trial observed that patients receiving 
alpha-tocopherol were less likely to progress from the milder 
state to the more severe state, according to the ALS Health 
State scale.91 In a recent retrospective case-control study, a 
high intake of vitamin E was associated with a 50%–60% 
decreased risk of developing ALS.93 Further clinical trials 
with longer follow-up or larger sample sizes are needed.
edavarone
Edaravone (MCI-186) is an agent widely used for cerebral 
ischemia in Japan that acts as a free-radical scavenger.94 
In a randomized blind trial, intraperitoneally administra-
tion of multiple doses of edaravone in an ALS mice model 
significantly slowed the motor decline and motor neuron 
degeneration of the transgenic mice, even when administered 
after the onset of the disease.94 Furthermore, high-dose eda-
varone treatment was associated with a significant decrease 
in the area of mutant SOD1 deposition in the spinal cord.94 
The favorable effects of the drug might be attributable to its 
primary antioxidant properties or alternatively to the reduc-
tion of mutant SOD1 accumulation.94
In an open-label phase II study of 20 patients with ALS, 
the intravenous administration of edavarone was safe and 
well tolerated and there was a suggestion of slowed disease 
progression, measured by the ALS-FRS scale during the 
six-month treatment period, compared with the six months 
before the administration of edavarone.95 Treatment with eda-
varone also resulted in a marked reduction of 3-nitrotyrosine, 
a marker of oxidative stress.95 A phase III clinical trial is 
undergoing in Japan.24
r(+) pramipexole
R(+) pramipexole is the enantiomeric homolog of the 
dopamine agonist used in Parkinson’s disease and can reduce 
oxidative stress in patients with ALS.96 In vitro and in vivo 
studies revealed that it is concentrated into the brain and 
mitochondria and efficiently scavenges reactive oxygen and 
nitrogen species,96,97 and blocks caspase activation.98 As it 
has less affinity for dopamine receptors than pramipexole, 
it should have fewer side effects.96 In SOD1 ALS transgenic 
mice, treatment with R(+) pramipexole prolongs survival.98 
A small open-label dose-escalation study on 30 ALS patients 
revealed a nonsignificant 17% reduction in the rate of decline 
of ALS-FRS in the group of patients receiving the highest 
dosage (60 mg/day).8,97 A study on safety and tolerability 
has just terminated the recruitment.23 Further studies are 
however warranted.
AeOL-10150
The manganese porphyrin AEOL-10150, is a small-molecule 
antioxidant analogous to the catalytic site of superoxide 
dismutase, that scavenges peroxynitrite and other deleterious 
oxidants.8,23 It has been indicated as a potential subcutaneous 
treatment for ALS.98 The administration of AEOL-10150 
at symptom onset markedly prolonged survival in SOD1 
transgenic mice.99–101 Recently, the single dose subcutaneous Neuropsychiatric Disease and Treatment 2009:5 587
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treatment with AEOL-10150 was safe and well tolerated in 
25 patients with ALS.102 A multiple dose phase II safety study 
is underway.24,102 Although there are limited data in humans 
with ALS, a recent meta-analysis of preclinical trials con-
ducted on SOD1 transgenic mice found that AEOL-10150 
can be considered the most promising compound for evalu-
ation in a treatment trial.103
Ammonium tetrathiomolybdate (TTM)
Ammonium tetrathiomolybdate (TTM) is a copper-chelating 
drug that is capable of removing a copper ion from copper-
thiolate clusters, such as SOD1.104 A recent preclinical study 
on SOD1 transgenic mice found that treatment with TTM sig-
nificantly delayed disease onset, slowed disease progression, 
and prolonged survival by approximately 20%, 42%, and 
25%, respectively.104 TTM was also effective in depressing 
the spinal copper ion level and inhibiting the lipid peroxidation, 
with a significant suppression of SOD1 enzymatic activity in 
SOD1.104 There are still no data on humans.
N-acetylcysteine
N-acetyl-L-cysteine is an antioxidant agent that reduces free 
radical damage.8 Preclinical studies in transgenic mice with 
SOD1 mutation showed that N-acetyl-L-cysteine signifi-
cantly extends survival and delayed onset of motor impair-
ment.105 However, in a double-blind placebo-controlled clinical 
trial on 110 ALS patients, acetylcysteine 50 mg/kg daily subcu-
taneous infusion did not result in a major increase in 12-month 
survival or a reduction in disease progression.106 Therefore, the 
beneficial effects of cysteine in ALS seem questionable.
TrO19622
TRO19622 is a cholesr-4-en-3-one steroidal oxime identified 
via through-put screening.107 TRO19622 may increase mito-
chondrial stability by directly bounding to two components of 
the mitochondrial permeability transition pore: the voltage-
dependent anion channel and the translocator protein.107 In vitro 
studies found that TRO19622 promotes motor neuron survival 
in a dose-dependent manner.107 In vivo, TRO19622 rescued 
motor neurons from axotomy-induced cell death promoted 
nerve regeneration.107 Finally, treatment with TRO19622 sig-
nificantly improved motor performances, delayed the onset of 
the disease and extended survival in SOD1transgenic mice.107 
There are still no data on safety and efficacy on humans.
Tamoxifen
Tamoxifen is a selective estrogen receptor modulator that 
belongs, as TRO19622, to the family of steroidal eoximes.8 
Along with the well known antineoplastic activity, tamoxifen 
may inhibit the action of protein kinase C and may bind the 
mitochondrial permeability transition pore.8 Preliminary 
results of a 24-month phase II clinical trial indicated a trend 
for survival benefit with administration of tamoxifen at the 
dose of 20 mg/day.108
Antiapoptotic
Minocycline
Minocycline is a tetracycline antibiotic that has antiapoptotic 
and anti-inflammatory effects in vitro (prevents microglial 
activation and caspase activation). Minocycline extends sur-
vival in mouse models of some neurological conditions, as 
ALS.109–111 Two double-blind, randomized, placebo-controlled 
phase II clinical trials demonstrated that the drug is safe and 
well tolerated in 42 ALS patients; 23,112 however these studies 
were not powered for efficacy.23 A recent multicenter, random-
ized placebo-controlled phase III trial on 412 patients found 
that minocycline in escalating doses of up to 400 mg/day 
for nine months has a harmful effect on patients with ALS. 
A faster ALS-FRS score deterioration and greater mortality 
(hazard ratio, 1.32; 95% confidence interval [CI]: 0.83–2.10; 
P = 0.23) was observed in the minocycline group than in the 
placebo group.113 These results indicate that minocycline is not 
effective in ALS patients.
TCH346
TCH346 is an antiapoptotic agent that binds to glyceralde-
hyde 3-phosphate dehydrogenase (GAPDH) and blocks the 
apoptotic pathway in which GAPDH is involved. TCH346 
treatment delayed disease onset and slowed the clinical course 
of the disease in the ALS mouse model.114 A small sample 
double-blind placebo-controlled clinical trial conducted on 
591 patients from Europe and North America failed to find 
any beneficial effect of TCH346 given at several dosages on 
disease progression in patients with ALS.115
N-benzyloxycarbonyl-Val-Asp-fluoromethylketone 
(zvAD-fmk)
N-benzyloxycarbonyl-Val-Asp-fluoromethylketone 
(zVAD-fmk) is a broad enzymatic caspase inhibitor.116 
Intraventricular administration of zVAD-fmk in the late 
presymptomatic stage significantly delayed disease onset 
and prolonged survival in SOD1 transgenic mice.116 Data 
on ALS patients are still not available.
Pentoxifylline
Pentoxifylline is a phosphodiesterase inhibitor that 
increases cellular cyclic AMP and GMP and demonstrates Neuropsychiatric Disease and Treatment 2009:5 588
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antiapoptotic properties.117 A randomized clinical trial 
conducted on 400 European ALS patients found that treatment 
with pentoxifylline as add-on to riluzole was not associated 
with appreciable effect on functional measures.117 Moreover, 
pentoxifylline had a negative effect on survival. At the end of 
follow-up period, 51.7% of patients were alive in the pentoxi-
fylline group compared to 59.7% in the placebo group (unad-
justed risk 1.28, P = 0.107; adjusted risk 1.43, P = 0.02).117
Anti-inflammatory
Cyclooxygenase (COX-2) inhibitors
The enzyme cyclooxygenase-2 (COX-2) has been proposed 
as an attractive therapeutic target in ALS because its increase 
in the spinal cord stimulates astrocytic glutamate release.118 
Elevated levels of COX-2 and prostaglandin E2 have been 
observed in the spinal cord of SOD1 mutant mice and ALS 
patients.118 Celecoxib, a COX-2 inhibitor has been shown 
to be beneficial in preclinical testing, prolonging survival 
of SOD1 mice.119,120 A 12-month double-blind placebo-
controlled clinical trial was conducted on 300 patients 
with ALS. Subjects were randomized (with a 2:1 ratio) to 
receive celecoxib (800 mg/day) or placebo for 12 months.121 
Treatment with celecoxib showed safe results but did not have 
a beneficial effect on the decline in muscle strength, vital 
capacity, motor unit number estimates, ALS-FRS score, or 
survival in patients with ALS.121
Nimesulide has been indicated as the preferential COX-2 
inhibitor because of has additional antioxidant properties 
and can be administered via multiple routes, including 
orally.23 Preclinical observations revealed that nimesulide 
administration decreases prostaglandin E2 levels in the 
spinal cord of SOD1G93A mice and preserves motor skill 
integrity.122 However, its putative mechanism of action is 
the same as celecoxib and safety concerns surrounding 
long-term administration of this medication class may 
limit the use of COX-2 inhibitors in patients with ALS.23 
Their combination with other compounds such as creatine 
is under evaluation.24
Glatiramer acetate
Glatiramer acetate, a combination of four amino acids, 
is the analogous of myelin basic protein and it is used to 
reduce the frequency of relapses in patients with multiple 
sclerosis.20 It requires subcutaneous administration and is 
believed to act by enhancing regulatory T-cell immunity.23,123 
In addition, it may also have antiglutamatergic and growth 
factor-stimulating effects.123 Results of preclinical studies are 
limited and conflicting, some studies found that it prolongs 
survival in SOD1 mutant mice,124 while others did not.125 In a 
phase II trial conducted on 20 ALS patients the drug showed 
safe, well tolerated results and affected the immune system 
at the dosage studied.126 A recent large-scale double-blind, 
randomized placebo-controlled multicenter trial on 366 ALS 
patients confirmed safety and tolerability of glatiramer 
acetate at a dose of 40 mg/day but did not show any beneficial 
effect of the drug on rate of deterioration of the ALS-FRS 
scale, or time to death, tracheostomy or permanent assisted 
ventilation.127 Further studies are required.
AM-1241
Cannabinoids produce anti-inflammatory actions via canna-
binoid receptor 1 and 2 (CB2) and delay the progression of 
neuroinflammation.128 AM-1241 is a selective agonist at the 
CB2 cannabinoid receptors, that are dramatically up-regulated 
in inflamed neural tissues associated with CNS disorders.128 
Animal studies on SOD1 mutant mice reported that the injec-
tions at symptom onset can dramatically prolong survival.128,129 
However, there is no experience with this compound on 
humans and administration is likely to be parenteral.23
Celastrol
Celastrol, a natural product from southern China, has 
multiple effects that can be relevant to ALS. It exerts potent 
anti-inflammatory and antioxidative effects, by suppression 
of tumor necrosis factor-α (TNF-α), interleukin-1B, and 
nitric oxide.23 It also acts potently to increase expression 
of heat shock proteins.130 The oral administration before 
the onset of symptoms significantly improved weight loss, 
motor performance and delayed the onset of ALS in SOD1 
transgenic mice.130 However, there is a lack of safety and 
pharmacokinetic data in humans with ALS.23
Thalidomide
Thalidomide, is an historical sedative and now is used again 
in the treatment of leprosy, myeloma and cachexia. It has 
a number of interesting mechanisms of action for neurode-
generative disorders such as ALS, including suppression 
of TNF-α.23 When administered orally to SOD1 mutant 
mice, it enhanced motor performance, decreased motor 
neuron cell death, and significantly prolonged life span.131 
However a small open-label study found no improvement 
in progression of the disease. In addition, treatment with 
thalidomide was associated with several side effects.132 
Further clinical trials are however underway.24 Because of 
thalidomide’s side effects, lenalidomide may offer a safer 
alternative.131,133Neuropsychiatric Disease and Treatment 2009:5 589
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Nordihydroguaiaretic acid
Nordihydroguaiaretic acid Iis a lipoxygenase inhibitor that 
inhibits TNF-α activation of microglia134 and enhances gluta-
mate uptake in motor neuronal cells.135 A recent animal study 
on SOD1 transgenic mice found that nordihydroguaiaretic acid 
extends survival and slowed motor dysfunction. These favorable 
effects were observed even when administration was begun rela-
tively late in life.134 There are still no data on ALS patients.
Pioglitazone
Pioglitazone is a peroxisome proliferator-activated receptor-γ 
(PPAR-γ) agonist. It is used as an oral antidiabetic, but may 
also act as potent anti-inflammatory drug.136 Three recent 
animal studies on SOD1 transgenic mice found that the oral 
administration of pioglitazone significantly improves muscle 
strength and body weight, delayed the disease onset and 
prolonged survival.136–138 To date, no information on safety 
and efficacy on ALS patients are available; however, a phase 
II clinical trial is ongoing.24
rO-28-2653
RO-28-2653 acts as an anti-inflammatory agent by specifically 
inhibiting the activation of matrix metalloprotease enzymes 
that digest the extracellular matrix. An increased expression 
of matrix metalloproteinases and the degradation of the extra-
cellular matrix in postmortem spinal cord tissue have been 
observed in ALS.139 RO-28-2653 prolonged survival in familial 
ALS mice if given before the onset of symptoms;139 however, 
the administration of the drug at disease onset did not signifi-
cantly improve survival time.139 Despite the unique mechanism 
of action among ALS relevant therapies, there is a lack of 
safety or efficacy data for this agent in ALS patients.24
ONO-2506
ONO-2506 is an enantiomeric homolog of valproic acid, 
which has multiple potential mechanisms for ALS, as anti-
inflammatory COX-2 inhibitor properties and antiglutamate 
functions.140 ONO-2506 also restores normal astrocytes func-
tions after brain damage and prevents reactive astrocytosis.140 
European phase I and II studies of 1,200 mg per day oral 
formulation have been conducted in humans with ALS, but 
results are not yet available.23,24 A phase III study has recently 
been initiated in Europe.140
Autophagy inducer
Lithium
Both in vitro and in vivo studies revealed that the autophagy 
pathway is involved during motor neuron death with a protec-
tive role.141 Lithium is a compound used as a mood stabilizer, 
which is neuroprotective in a variety of disease models.141 
At low doses is a well-known autophagy inducer that clears 
misfolded proteins and altered mitochondria from motor 
neurons. In addition, lithium preserves mitochondria and 
sustains their genesis.141 Finally, lithium has been reported to 
decrease glial proliferation in the ALS spinal cord and induces 
sprouting in cortico-spinal fibers.142 Preclinical study on SOD1 
transgenic mice found that lithium delayed disease onset and 
duration and augmented the life span.143 These effects were 
associated with the activation of autophagy, an increase in the 
number of the mitochondria in motor neurons and suppression 
of reactive astrogliosis. In a small sample open label study, daily 
doses of lithium, leading to plasma levels ranging from 0.4 to 
0.8 mEq/liter, delayed disease progression in on 44 patients 
affected by ALS.143 Larger clinical trials are ongoing.24
Protein aggregation: Histone deacetylase 
inhibitors and heat-shock protein 
gene inductors
Sodium phenylbutyrate
Sodium phenylbutyrate improves transcription and post-
transcriptional pathways, by inhibiting histone deacety-
lase enzyme. Transcription dysregulation and consequent 
abnormal protein aggregation play a role in the pathogenesis 
of ALS.3 Ubiquitin cytosolic inclusions indeed represent one 
of the pathologic hallmark of ALS.8 In the mouse model of 
ALS sodium phenylbutyrate promoted cell survival, alone or 
in combination with riluzole.144,145 A recent 20-week open-
label study found that the oral administration of sodium 
phenylbutyrate to 26 ALS patients was safe and tolerable.146 
Blood histone acetylation levels were significantly increased 
after sodium phenylbutyrate administration, even at the low-
est dosage (9 g/day).146 Further animal studies and clinical 
trials on long-term safety and efficacy are required.
valproic acid
Valproic acid is a well-known antiepileptic drug that may 
modulate transcriptional dysregulation by acting as a his-
tone deacetylase inhibitor.147,148 It also may upregulate the 
antiapoptotic protein Bcl-2.147,148 Preclinical studies on SOD1 
mutant mice gave discordant results; 149–152 some studies found 
that it prolongs survival when given before or at symptoms 
onset,149,150 while others did not.151,152 Furthermore, a recent 
sequential clinical trial found that treatment with valproic acid, 
at a dose used in epilepsy, is safe but does not show a benefi-
cial effect on survival or disease progression in 163 patients 
with ALS.153 Other clinical trials are underway.24Neuropsychiatric Disease and Treatment 2009:5 590
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Scriptaid
Scriptaid is a small molecule that acts as a histone deacetylase 
inhibitor. In vitro studies found that treatment with scriptaid 
disrupts aggresome formation in cultured cells transfected 
with mutant SOD1.154 Trials on safety and efficacy of this 
compound both in animal models and ALS patients are still 
unavailable.
Arimoclomol
Arimoclomol amplifies heat shock protein gene expression and 
induces heat-shock protein during cell stress.155 This drug may 
interfere with protein aggregation and apoptosis, mechanisms 
likely to be involved in ALS pathogenesis. It significantly 
prolonged survival in SOD1 mice, when administered either 
before the onset or at the symptoms onset.155,156 In a recent 
early-stage clinical trial it was administered orally at three 
different dosages to 84 patients with ALS over 12 weeks.157 
The drug showed safe and well tolerated results at doses up 
to 300 mg/day.157 An efficacy study in ALS patients has been 
planned but is not yet open for recruitment, because the drug 
has been placed on hold by the FDA until results of preclinical 
toxicology studies become available.158
Discussion
ALS remains a devastating disease that dramatically reduces 
quality of life and survival of patients, despite in recent years 
advances in understanding the mechanisms of ALS have been 
provided by the development of animal models of ALS and 
a large number of drugs have been tested.
The management of ALS patients is still supportive and 
symptoms-based and, actually, riluzole is the only compound 
that demonstrated a beneficial effect on ALS patients, but with 
only modest increase in survival. Although several drugs (such 
as creatine, celecoxib, IGF-1, CNF, gabapentin, topiramate, 
lamotrigine, minocycline, thalidomide, valproate, vitamin E) 
gave positive results in preclinical animal studies, none of 
these compounds, when tested in humans, significantly pro-
longed survival or improved quality of life of ALS patients.
Several factors have been implicated in the explaining 
the predominantly negative results of numerous randomized 
clinical trials in ALS, including methodological problems 
in the use of animal-drug screening, the lack of assessment 
of pharmacokinetic profile of the drugs and methodological 
pitfalls of clinical trials.
Use of animal-drug screening
The therapeutic successes obtained in the SOD1 ALS 
rodent model has not translated into effective therapy for 
ALS patients. Riluzole, the only effective drug in ALS, was 
developed without the use of the SOD1 transgenic mice 
model.158 Based on these observations, the utility of animal 
models in the preclinical phase for identifying therapeutic 
agents in ALS has been doubted.23,103
Several possible explanations are conceivable for the 
discrepancy between successful animal studies and inef-
fective clinical trials in humans. First, most of the available 
therapeutic trials for ALS conducted on mice model present 
several methodological pitfalls, as pointed out by recent meta-
analyses.103,159 First, the lack of control in most of the studies 
for critical biological confounding variables, including sex, 
that should be ruled out when designing and interpreting 
results from efficacy studies.103,159 A second explanation 
could be that treatment has been started before the onset of 
symptoms in more than 80% of the studies.103 Although this 
approach may be more effective in showing a delay in the 
onset or slowing in the progression of the disease, it cannot 
be used in patients with sporadic ALS, as to date subjects 
who are at high risk for developing ALS cannot be identified. 
Third, only the minority of studies was randomized and inves-
tigators were blinded in an even smaller number.103
Furthermore, the intra-species differences in pharmacoki-
netics, difficulties in establishing dose equivalence to obtain 
in humans a biologic activity similar to that observed in mice, 
the difference between laboratories in the design of the ani-
mal study, may also concur to explain the contrast between 
results of preclinical studies and ALS clinical trials.8,23,103
Established consensus guidelines have been therefore 
advocated to ensure that ALS animal drug studies are con-
ducted in a uniform manner.23 With this objective, a recent 
study established several parameters for optimal study 
design in the SOD1 transgenic mouse model.159 Using these 
new study design criteria several compounds (minocycline, 
creatine, celecoxib, sodium phenylbutyrate, ceftriaxone, 
thalidomide, and riluzole) were retested and no benefit on sur-
vival was found for any compounds, including riluzole.159
Finally, another possible explanation for the contrast 
between results of preclinical studies and ALS clinical trials may 
be that the current mouse model of familial ALS is not able to 
evaluate the drug effect in patients with sporadic ALS. Animal 
drug-screening studies in ALS almost exclusively utilized 
the mutant SOD1 (G93A) mouse, but it remains to be firmly 
demonstrated that the SOD1 transgenic mouse models are an 
accurate and useful model for sporadic ALS.103,159 The role of 
biochemically altered SOD1 in sporadic ALS remains specula-
tive and some pathogenetic mechanisms are different between 
familial and sporadic ALS.3 Alternative models that better Neuropsychiatric Disease and Treatment 2009:5 591
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represent pathological features observed in sporadic ALS should 
be therefore obtained.23 However, until a model of sporadic ALS 
will be developed, a possible strategy will be to require multiple 
preclinical information both from in vitro and in vivo studies 
before the start of clinical trials on ALS patients.
Correct assessment 
of pharmacokinetic profile
There has been a tendency for potentially beneficial candi-
dates to move rapidly to large ALS clinical trials, before an 
adequate assessment of parameters as the pharmacokinetic 
profile, the safety/toxicity properties. Dose-ranging studies 
are a prerequisite to phase III studies to determine the most 
effective and safe dosage.23 This is particularly relevant if we 
consider that the tolerability of a dose in healthy patients may 
not be taken as indication that the same dose will be safe in 
patients with ALS. In the clinical trial of topiramate in ALS, 
the frequency of adverse events was higher in patients with 
ALS compared to that observed in patients with epilepsy,34 
probably relating to the dehydration and malnutrition in 
patients with ALS. Finally, the lack of ability of a drug to 
cross the human blood–brain barrier may not represent an 
important issue for the efficacy of newly developed drugs in 
ALS. Recent studies indeed found that blood–brain barrier 
is compromised in the areas of motor neuron degeneration 
of ALS mouse models and that tight junction proteins are 
down-regulated in ALS patients.160,161
Methodological pitfalls of ALS 
clinical trials
Several methodological pitfalls have been underlined in the 
design of most of ALS clinical trials, including the small 
sample size, the inclusion of heterogeneous populations, the 
short follow-up, and the use of inadequate efficacy measures. 
The small sample size is believed to prevent the assessment of 
mild/moderate drug effects, as we may expect in ALS.162
The inclusion of patients with variable disease duration, 
site of onset (bulbar vs spinal), values of forced vital capacity 
may represent a remarkable source of bias.162 The enrolment 
of ALS of newly diagnosed cases from population-based 
cohorts has been proposed to test the efficacy of new phar-
maceutical compounds, because an early start of treatment 
is an important issue in evaluating efficacy for devastating 
disease, such as ALS.162 Population-based cohorts may 
offer the advantages of a greater potential response to a 
given treatment, when compared to prevalent cohorts with 
long-lasting disease, as observed by studies conducted on 
riluzole.10,11 Moreover, a rigorous control of confounding 
factors is necessary in ALS clinical trials, given the presence 
of prognostic indicators that may significantly affect the 
primary end-points of the study.
The study end-points are an important issue for the choice 
of the study design. A wide range of end-points have been 
included, from death or tracheostomy, gastrostomy, mechanical 
ventilation, and a number of disability measures, like ALS-
FRS.23 Another crucial point is the short duration (6–12 months) 
of the large majority of clinical trials; this is an important issue 
to evaluate the efficacy at the late stage of the disease.10,11
Comments
We believe that the development of more potent riluzole 
analogs should be an important issue in the near future, as 
riluzole is the only therapy to date that slows disease progres-
sion in patients with ALS.6
Until this is confirmed, the use of a single medication 
that targets more than one pathogenic pathway or combining 
agents with different mechanisms of action could represent a 
therapeutic approach to the disease. Although multiple drug 
interactions might hypothetically increase the incidence of 
side effects, such combination therapy may be successful, as 
observed in oncology.23
Clinical trials including “cocktail therapies” should also be 
designed using new drugs as add-on therapies to riluzole.23 Pre-
clinical studies in SOD1 transgenic mice indicated that therapy 
combinations are more effective than individual agents.119,144 This 
approach has recently been considered in a phase II clinical trial 
and it appeared feasible, efficient, and has been demonstrated 
some beneficial effect on ALS patients.89 Furthermore, important 
news should be provided in the next years by research focused 
on drug delivery via viral vectors or compounds interfering with 
transcriptional dysregulation, protein aggregation, and disease-
causing mutations. Thus, results from ongoing trials of phenyl-
butyrate (which may reverse transcriptional dysregulation) and 
arimoclomol (which may mediate protein aggregation) will 
provide important information for everyday clinical practice.
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